- Janux Therapeutics ( NASDAQ: JANX ) said it submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) seeking to start a trial of cancer drug JANX008 in humans.
- The company added that JANX008 is in development to treat EGFR-expressing solid tumors, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), renal cell carcinoma (RCC), and squamous cell carcinoma of the head and neck (SCCHN).
- "We are proud to announce today the submission of Janux’s second IND – a critical milestone for our TRACTr platform as we advance our broad pipeline of next generation immunotherapies," said Janux President and CEO David Campbell.
For further details see:
Janux seeks FDA nod to start trial of cancer drug JANX008